Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Anti-Cancer Drugs
|
September 4, 2008
Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial
Reiki Nishimura, Takeshi Tominaga, Morihiko Kimura, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
June 25, 2015
Efficacy and safety of an amino acid jelly containing coenzyme Q10 and L-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01)
Satoru Iwase, Takashi Kawaguchi, Daisuke Yotsumoto, et al.
Anticancer Research
|
July 2, 2014
Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer
Tsutomu Takashima, Takahiro Nakayama, Katsuhide Yoshidome, et al.
Scientific Reports
|
May 20, 2022
Development of an intraoperative breast cancer margin assessment method using quantitative fluorescence measurements
Hiroki Ueo, Itsushi Minoura, Hiroaki Ueo, et al.
Anticancer Research
|
March 31, 2021
First-line Gemcitabine <i>Versus</i> Treatment of Physician's Choice for Metastatic Breast Cancer: A Prospective Cohort Study
Shinya Yamamoto, Kazutaka Narui, Takashi Ishikawa, et al.
Scientific Reports
|
March 3, 2026
Multicenter ex vivo evaluation of an α-mannosidase-targeted fluorescent probe for intraoperative margin assessment in breast cancer
Hiroki Ueo, Hiroaki Ueo, Takako Doi, et al.
Anticancer Research
|
May 16, 2009
Feasibility of AC/EC followed by weekly paclitaxel in node-positive breast cancer in Japan
Takashi Ishikawa, Satoru Shimizu, Kiyofumi Katayama, et al.
Breast (Edinburgh, Scotland)
|
June 24, 2019
Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101
Kazutaka Narui, Takashi Ishikawa, Daisuke Shimizu, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Anti-Cancer Drugs
|
September 4, 2008
Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial
Reiki Nishimura, Takeshi Tominaga, Morihiko Kimura, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
June 25, 2015
Efficacy and safety of an amino acid jelly containing coenzyme Q10 and L-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01)
Satoru Iwase, Takashi Kawaguchi, Daisuke Yotsumoto, et al.
Anticancer Research
|
July 2, 2014
Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer
Tsutomu Takashima, Takahiro Nakayama, Katsuhide Yoshidome, et al.
Scientific Reports
|
May 20, 2022
Development of an intraoperative breast cancer margin assessment method using quantitative fluorescence measurements
Hiroki Ueo, Itsushi Minoura, Hiroaki Ueo, et al.
Anticancer Research
|
March 31, 2021
First-line Gemcitabine <i>Versus</i> Treatment of Physician's Choice for Metastatic Breast Cancer: A Prospective Cohort Study
Shinya Yamamoto, Kazutaka Narui, Takashi Ishikawa, et al.
Scientific Reports
|
March 3, 2026
Multicenter ex vivo evaluation of an α-mannosidase-targeted fluorescent probe for intraoperative margin assessment in breast cancer
Hiroki Ueo, Hiroaki Ueo, Takako Doi, et al.
Anticancer Research
|
May 16, 2009
Feasibility of AC/EC followed by weekly paclitaxel in node-positive breast cancer in Japan
Takashi Ishikawa, Satoru Shimizu, Kiyofumi Katayama, et al.
Breast (Edinburgh, Scotland)
|
June 24, 2019
Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101
Kazutaka Narui, Takashi Ishikawa, Daisuke Shimizu, et al.
Page
of 2